A Phase II Study to Assess the Efficacy and Safety of a Single Inhaled Dose of Albuterol Sulfate Dry Powder Via the Trivair Deposition System Versus Albuterol Sulfate HFA pMDI in Patients With Intermittent or Persistent Mild Asthma.

Trial Profile

A Phase II Study to Assess the Efficacy and Safety of a Single Inhaled Dose of Albuterol Sulfate Dry Powder Via the Trivair Deposition System Versus Albuterol Sulfate HFA pMDI in Patients With Intermittent or Persistent Mild Asthma.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Salbutamol (Primary) ; Salbutamol sulfate
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Acerus Pharmaceuticals
  • Most Recent Events

    • 09 Mar 2018 Planned End Date changed from 1 Jun 2011 to 1 Oct 2015.
    • 09 Mar 2018 Planned primary completion date changed from 1 Jun 2011 to 1 Apr 2013.
    • 09 Mar 2018 Planned initiation date changed from 1 Mar 2011 to 1 Nov 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top